TNI Medical AG

TNI Medical AG develops innovative therapies to support patients with respiratory insufficiency, focusing on advanced High Flow Therapy solutions for improved patient outcomes in healthcare settings. TNI Medical AG, founded in 2007 and headquartered in Wurzburg, Germany, specializes in respiratory therapies. The company has secured 3 funding deals, with the latest being EUR 3. 00 mn led by Pathena on March 19, 2020.

TNI Medical AG was targeted for acquisition by Masimo Corporation, expected to close in Q2 2020. Ewald Anger serves as the CEO of the company. TNI Medical AG specializes in innovative therapies aimed at patients suffering from respiratory insufficiency, particularly focusing on their proprietary High Flow Therapy solution. This therapy enhances respiratory support by delivering high flows of oxygen-enriched air via nasal insufflation, improving patient comfort and compliance.

Their customer base includes healthcare providers and institutions treating respiratory disorders, including those affected by conditions such as COVID-19. The company has established its products across international markets in Europe, North America, and Asia, meeting the global demand for advanced respiratory support technologies. The revenue structure of TNI Medical AG primarily derives from direct sales to healthcare institutions and partnerships with medical suppliers. Their High Flow Therapy devices and consumables are sold through negotiated contracts tailored to each client's needs.

The firm operates on a B2B model, where hospitals and clinics procure its products to enhance respiratory management. Pricing plans are established through agreements with healthcare providers, ensuring solutions that optimize treatment efficacy for patients. The flagship High Flow Therapy solutions are central to the company’s revenue generation strategy. TNI Medical AG aims to expand its product line and market reach with its recent funding of EUR 3.

00 mn. The company plans to develop new products designed for advanced respiratory care, although specific release dates have not been disclosed. Geographically, TNI Medical AG intends to target additional markets in Europe and Asia for expansion by 2023. The funds raised in the most recent deal will be pivotal in supporting these initiatives, along with the strategic acquisition by Masimo Corporation that is anticipated to bolster its operational capabilities.